Literature DB >> 9511031

Therapy of bacterial vaginosis.

P E Hay1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1998        PMID： 9511031     DOI： 10.1093/jac/41.1.6

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN： 0305-7453            Impact factor:   5.790


× No keyword cloud information.
  8 in total

1.  In vitro activities of Garenoxacin (BMS 284756) against 108 clinical isolates of Gardnerella vaginalis.

Authors:  Ellie J C Goldstein; Diane M Citron; C Vreni Merriam; Yumi A Warren; Kerin L Tyrrell; Helen T Fernandez
Journal:  Antimicrob Agents Chemother       Date:  2002-12       Impact factor: 5.191

2.  Recurrent Bacterial Vaginosis.

Authors: 
Journal:  Curr Infect Dis Rep       Date:  2000-12       Impact factor: 3.725

3.  Bacterial vaginosis.

Authors:  F Keane; C A Ison; H Noble; C Estcourt
Journal:  Sex Transm Infect       Date:  2006-12       Impact factor: 3.519

4.  Social and sexual risk factors for bacterial vaginosis.

Authors:  S Smart; A Singal; A Mindel
Journal:  Sex Transm Infect       Date:  2004-02       Impact factor: 3.519

5.  Bacterial communities in women with bacterial vaginosis: high resolution phylogenetic analyses reveal relationships of microbiota to clinical criteria.

Authors:  Sujatha Srinivasan; Noah G Hoffman; Martin T Morgan; Frederick A Matsen; Tina L Fiedler; Robert W Hall; Frederick J Ross; Connor O McCoy; Roger Bumgarner; Jeanne M Marrazzo; David N Fredricks
Journal:  PLoS One       Date:  2012-06-18       Impact factor: 3.240

6.  Efficacy of clindamycin vaginal ovule (3-day treatment) vs. clindamycin vaginal cream (7-day treatment) in bacterial vaginosis.

Authors:  J Sobel; J F Peipert; J A McGregor; C Livengood; M Martin; J Robbins; C P Wajszczuk
Journal:  Infect Dis Obstet Gynecol       Date:  2001

7.  Metronidazole versus lactic acid for treating bacterial vaginosis (VITA): protocol for a randomised controlled trial to assess the clinical and cost effectiveness of topical lactic acid gel for treating second and subsequent episodes of bacterial vaginosis.

Authors:  Lindsay Armstrong-Buisseret; Clare Brittain; Miruna David; Gillian Dean; Frances Griffiths; Trish Hepburn; Louise Jackson; Joe Kai; Alan Montgomery; Tracy Roberts; Sukhwinder Thandi; Jonathan D C Ross
Journal:  Trials       Date:  2019-11-27       Impact factor: 2.279

Review 8.  On the pathway to better birth outcomes? A systematic review of azithromycin and curable sexually transmitted infections.

Authors:  R Matthew Chico; Berkin B Hack; Melanie J Newport; Enesia Ngulube; Daniel Chandramohan
Journal:  Expert Rev Anti Infect Ther       Date:  2013-11-06       Impact factor: 5.091
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.